It's not just celebrities and TikTok creators jumping on the weight loss drug hype - more than 500,000 people in the UK are ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...

(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for ...

Some people may turn to private healthcare providers in order to get their hands on the weight loss jabs. However, Britons ...

A little over two years ago, a whisper of a new drug was abundant ... the weight loss industry. In Hollywood, it became a coveted accessory, for everyone else an injectable tool for mastering ...

The New York City-based biotech firm is developing injectable and oral drugs to ... working capital and other general purposes. The weight-loss drug market, which is estimated by analysts to ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said ... that its compounded drug, "MEGALean - Premium Tirzepatide Injections", is clinically tested to facilitate weight loss and improve ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.